Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19492330 | 0.78 | ADRB1 (0.31) | ADRB1 | |
| SCHEMBL19362479 | 0.78 | ADRB1 (0.31) | ADRB1 | |
| SCHEMBL7050888 | 0.76 | — | — | |
| SCHEMBL5314783 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL6484703 | 0.75 | ALDH1A1 (0.30) | — | |
| SCHEMBL8584915 | 0.74 | — | — | |
| SCHEMBL72235 | 0.73 | POLB (0.35) | POLBSMN1; SMN2 | |
| SCHEMBL22430210 | 0.73 | CHRM5 (0.31) | — | |
| SCHEMBL517802 | 0.73 | ADRB1 (0.37) | ADRB1 | |
| Hydrochloric Acid SCHEMBL4229103 | 0.71 | POLB (0.34) | POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071530-B | Fused pyrimidine piperidine ring derivatives, and preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3466948-B1 | FUSED PYRIMIDINOPIPERIDINE DERIVATIVE, AND MANUFACTURING METHOD AND APPLICATION THEREOF | SHANGHAI ALLIST PHARMACEUTICALS CO LTD (CN) | 2021-01-20 | — | — | EP | disclosed |
| US-10544144-B2 | Fused pyrimidine piperidine cyclic derivative, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICAL AND MEDICAL TECHNOL (CN) | 2020-01-28 | — | — | US | disclosed |
| US-20190218213-A1 | FUSED PYRIMIDINE PIPERIDINE CYCLIC DERIVATIVE, PREPARATION PROCESS AND USE THEREOF | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2019-07-18 | — | — | US | disclosed |
| EP-3466948-A1 | FUSED PYRIMIDINOPIPERIDINE DERIVATIVE, AND MANUFACTURING METHOD AND APPLICATION THEREOF | Shanghai Allist Pharmaceutical and Medical Technology Corporations (CN) | 2019-04-10 | — | — | EP | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
| US-5063208-A | Cardiovascular disorders, vision defects | ABBOTT LABORATORIES (US) | 1991-11-05 | — | — | US | disclosed |
| EP-0416393-A1 | Peptidyl difluorodiol renin inhibitors | ABBOTT LABORATORIES (US) | 1991-03-13 | — | — | EP | disclosed |
| EP-0410260-A2 | Peptidyl aminodiol renin inhibitors | ABBOTT LABORATORIES (US) | 1991-01-30 | — | — | EP | disclosed |
| WO-1989010751-A1 | FUNCTIONALIZED PEPTIDYL AMINODIOLS AND -TRIOLS | ABBOTT LABORATORIES (US) | 1989-11-16 | — | — | WO | disclosed |
| EP-0341602-A2 | Renin-inhibiting functionalized peptidyl aminodiols and - triols | ABBOTT LABORATORIES (US) | 1989-11-15 | — | — | EP | disclosed |
| EP-0307837-A2 | Renin-inhibiting peptidyl heterocycles | ABBOTT LABORATORIES (US) | 1989-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | ADRB1 1876/4885POLB 2753/4885SMN1; SMN2 1141/4885 |
| US-20190218213-A1 | FUSED PYRIMIDINE PIPERIDINE CYCLIC DERIVATIVE, PREPARATION PROCESS AND USE THEREOF | FGFR1, FGFR4, FGFR2 | ADRB1 3203/4885POLB 1030/4885SMN1; SMN2 3406/4885 |
| US-10544144-B2 | Fused pyrimidine piperidine cyclic derivative, preparation process and use thereof | FGFR1, FGFR4, FGFR2 | ADRB1 3203/4885POLB 1030/4885SMN1; SMN2 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.